Lyell Immunopharma, Inc. LYEL
Lyell Immunopharma, Inc. (Nasdaq: LYEL) is an oncology drug developer. Its lead program, rondecabtagene autoleucel (ronde-cel, LYL314), is in Phase 3 for relapsed/refractory large B-cell lymphoma (2L Phase 3 head-to-head; 3L+ pivotal single-arm). Its next catalyst on record is ronde-cel PiNACLE: Additional data from pivotal single-arm trial (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: ronde-cel PiNACLE — Additional data from pivotal single-arm trial (H2 2026). 5 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| ronde-cel PiNACLE-H2H (Phase 3, vs axi-cel or liso-cel) | 2L relapsed/refractory LBCL | cell therapy | Phase 3 |
| ronde-cel PiNACLE (pivotal single-arm, expansion of Phase 1/2 3L+ cohort) | 3L+ relapsed/refractory LBCL | cell therapy | Phase 2 |
| LYL273 (GCC-targeted CAR T) | metastatic colorectal cancer | cell therapy | Phase 1 |
| Undisclosed-target armed solid tumor CAR T | solid tumors | cell therapy | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 oncology companies
- Merck & Co., Inc. MRK
- Astrazeneca PLC AZN
- Bristol Myers Squibb Co BMY
- BeOne Medicines Ltd. ONC
- Revolution Medicines, Inc. RVMD
- Genmab A/S GMAB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.